bluebird bio, Inc. (BLUE)
| Market Cap | 48.96M |
| Revenue (ttm) | 103.95M |
| Net Income (ttm) | -199.98M |
| Shares Out | 9.79M |
| EPS (ttm) | -20.59 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 941,756 |
| Open | 4.99 |
| Previous Close | 4.99 |
| Day's Range | 4.98 - 5.01 |
| 52-Week Range | 3.20 - 28.60 |
| Beta | 0.32 |
| Analysts | Hold |
| Price Target | 44.60 (+792.0%) |
| Earnings Date | May 14, 2025 |
About BLUE
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company’s product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development... [Read more]
Financial Performance
In 2024, bluebird bio's revenue was $83.81 million, an increase of 184.12% compared to the previous year's $29.50 million. Losses were -$240.72 million, 13.6% more than in 2023.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for BLUE stock is "Hold." The 12-month stock price forecast is $44.6, which is an increase of 792.00% from the latest price.
News
bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today reminds all stockholders to promptly tender their shares into the tender offer by Carlyle and ...
Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions
SOMERVILLE, Mass.--(BUSINESS WIRE)--As previously announced on May 14, 2025, Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”)...
Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital
Bluebird bio and Carlyle Group and SK Capital Partners said on Wednesday that the private equity firms have offered $5 per share upfront to takeover the gene therapy maker.
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”), Carlyle (NASDAQ: CG) (“Carlyle”) and SK Capital Partners, LP (“SK Capital”) today announced they have amended their ...
Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender of...
Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”), Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings...
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd. (“...
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps
Bluebird Bio, Inc. BLUE received an unsolicited, non-binding written proposal from Ayrmid Ltd. on Friday.
Bluebird bio receives non-binding bid for up to $110.5 million
Gene therapy maker bluebird bio said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8% at $4.40 in extended trading.
Bluebird Bio Reviewing Buyout Offer From Ayrmid for Up to $110.5 Million -- Update
Bluebird Bio has received a competing bid from Ayrmid to buy the cash-strapped gene-therapy company in a deal potentially valued at up to $110.5 million.
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today confirmed it has received an unsolicited non-binding written proposal (the “Ayrmid Proposal”) from Ayrmid Ltd (...
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of blueb...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc.
NEW YORK , Feb. 21, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by bluebird bio, Inc. (NASDAQ: BLUE) and its board of directors concerning the proposed ac...
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million. Bluebird makes three gene therapies: Zynteglo for beta thalassemia, Lyfgenia for sickle cell disease...
bluebird bio Stock Alert - Kehoe Law Firm, P.C. Investigating the Fairness and Adequacy of the Proposed Acquisition of bluebird bio by Investment Firms in Collaboration with Biotech Execs
PHILADELPHIA, PA / ACCESS Newswire / February 21, 2025 / Kehoe Law Firm, P.C. is investigating potential claims on behalf of investors of bluebird bio (NASDAQ:BLUE) regarding the adequacy and fairness...
Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch
Gene therapy maker Bluebird bio said on Friday it would be taken private by Carlyle and SK Capital Partners, ending its tumultuous journey in the public markets as it struggled with a severe cash crun...
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today announced that it has entered into a definitive agreement to be acquired by funds managed by global investment ...
High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models
Deshawn "DJ" Chow is one of just over 100 sickle cell patients who have undergone treatment with new gene therapies. CVS Health CEO David Joyner said private insurers and employer-sponsored health pla...
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced new and updated data from LYFGENIA™ (lovotobegligene autotemcel, or lovo-cel) gene therapy for patients with sickl...
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with betibeglogene...
bluebird bio Announces 1-for-20 Reverse Stock Split
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it will proceed with a 1-for-20 reverse stock split (“Reverse Stock Split”)...
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio”) today announced it has reached an agreement with the Center for Medicare and Medicaid Innovation to offer an outc...
FDA investigates risk of blood cancers from bluebird bio's gene therapy
The U.S. Food and Drug Administration said on Wednesday it is investigating reports of blood cancers in patients who were treated with bluebird bio's gene therapy Skysona.
My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys
Investment activity in October focused on Business Development Companies, with $1,300 added to the market. Adjusted dividend income in October of $789, up 25% Y/Y and up 11% sequentially. Main picks i...
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
On Thursday, Bluebird Bio Inc. BLUE reported a third-quarter EPS loss of 31 cents, compared to a loss of 80 cents a year ago, beating the consensus loss of 36 cents.